Thymagen

What is it?

Thymagen is a synthetic dipeptide (Glu-Trp) framed as the short-peptide successor to Thymalin: same thymic/immune target as the original tissue extract, distilled down to two amino acids. It’s part of the second generation of the Khavinson bioregulator family — synthetic short peptides (di-, tri-, tetrapeptides) designed to reproduce the active fragment of the original organ-extract complexes. Site tier is Emerging (1 study, 0 human).

What does it do in my body?

Claimed mechanism: stimulates thymic epithelial-cell activity, supporting T-cell maturation and differentiation in the aging thymus — the same organ target as Thymalin, at a much more distilled molecular level.

This sits inside the broader Khavinson-family theoretical claim that short tissue-derived peptides can cross cell and nuclear membranes and modulate gene transcription in a tissue-specific way. Family-wide in-vitro work supports the underlying nuclear-penetration mechanism: short Khavinson peptides penetrate HeLa-cell nuclei and interact with DNA (Fedoreyeva et al. 2011, Biochemistry (Mosc), 22117547).

How can it help me?

• Where the science stands: Thin — site tier Emerging (1 study, 0 human); animal/in-vitro only

The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.

Is it dangerous? What are the side effects?

The reported adverse-event profile across the family is mild and uncommon in the Russian literature: occasional injection-site reactions, transient mild headache early in a cycle. No serious AEs documented at standard doses.

The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space. Buyers typically source these from forum links with no way to verify identity or purity, and counterfeit/mislabeled product is the most common failure mode for exactly these compounds. Third-party COA verification matters more here than for almost any other peptide class.

Regulatory status: Thymagen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance. Note that the family prototype, Thymalin (and the related cortex peptide Cortexin), holds a clinical-use approval in Russia — that approval does not extend to Thymagen or to the US.

Part 1 — How to reconstitute it

What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.

The exact bacteriostatic-water volume and resulting concentration for Thymagen are covered in the dosing notes and the deeper-science view. Confirm the right volume for your vial before mixing.

How to mix it

• Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
• Swirl gently to dissolve. Never shake — shaking can damage the peptide.
• Store the reconstituted vial refrigerated and out of light.
• Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.

Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.

Part 2 — Typical dosing

Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.

The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.

Educational purposes only — this reflects what Russian-school protocols and the peptide community actually use, stated plainly; it is not medical advice.

There is no Western-validated dosing protocol for Thymagen. What exists is the Khavinson-school cycle pattern shared across the family:

• Cycle structure: a short course — typically 10–20 consecutive days — followed by a long rest, repeated 2–3 times per year. The framework claims effects persist 2–3 months past the end of a cycle — asserted by the Khavinson program, not independently confirmed.
• Dose: as a synthetic short dipeptide, community subcutaneous dosing converges around ~100–200 mcg/day over the 10–20 day cycle; some Khavinson-family short peptides are also sold as oral capsules or sublingual drops in the Russian retail market per-peptide specifics.
• Storage: lyophilized powder is stable cold; once reconstituted with bacteriostatic water, refrigerate and use within roughly 28 days.

Because per-peptide human dose-finding data doesn’t exist for this family, treat every number above as community/Russian-protocol convergence, not a validated dose.

Turning milligrams into syringe units. On a U-100 syringe, 100 units = 1 mL, so 1 unit = 0.01 mL. At a concentration of C mg/mL, a dose of D mg = D ÷ C mL = (D ÷ C) × 100 units. Example: at 5 mg/mL, a 0.5 mg dose = 0.1 mL = 10 units. Your exact units depend on your own vial's mg and how much bacteriostatic water you added — use the same concentration you mixed above.

What should I avoid combining — and what's synergistic?

Thymagen doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.

How can I buy this?